Market Cap (In KRW)
116.06 Billion
Revenue (In KRW)
-
Net Income (In KRW)
-11.61 Billion
Avg. Volume
5.02 Million
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1733.0-17310.0
- PE
- -
- EPS
- -
- Beta Value
- 1.468
- ISIN
- KR7299660001
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Yuil Kang Chang
- Employee Count
- -
- Website
- http://www.cellid.co.kr
- Ipo Date
- 2019-02-19
- Details
- Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
More Stocks
-
00279KAMOREPACIFIC Group
00279K
-
0138
-
RANJFRandstad N.V.
RANJF
-
SFOSF
-
VLEEYValeo SE
VLEEY
-
KC4KONE Oyj
KC4
-
0HK4
-
SVNLF